drugset / Trial / NCT01552408

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408

Phase 1/2 Completed 29 enrolled David M. Brown, M.D. Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan retinal photocoagulation in patients with CSME-CI secondary to diabetes mellitus (Type 1 or 2).

Timeline

Start
2012-03
Primary completion
2017-05-18
Completion
2017-05-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.3 mg Intravitreal